Fasken Martineau DuMoulin LLP advised the Underwriter in connection with Medexus Pharmaceuticals’s offering. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) closed its bought-deal public offering of 3,389,900...
You must be a Standard 1 Year member to access this content.
Fasken Martineau DuMoulin LLP advised Elemental Altus Royalties Corp. on the acquisition. Elemental Altus Royalties Corp. (TSXV: ELE) (OTCQX: ELEMF) completed the acquisition of two existing...
You must be a Standard 1 Year member to access this content.
Fasken Martineau DuMoulin LLP advised Elemental Altus Royalties Corp. on the transaction. Elemental Altus Royalties Corp. completed the acquisition of two existing royalties from RCF Opportunities Fund...
You must be a Standard 1 Year member to access this content.
Fasken Martineau DuMoulin LLP advised the Placement Agent in connection with The Cannabist Company Holdings Inc. offering. On September 21, 2023, The Cannabist Company Holdings Inc.(NEO:...
You must be a Standard 1 Year member to access this content.
Fasken Martineau DuMoulin LLP advised BULGOLD Inc. in the transaction. BULGOLD Inc. (the “Company”) announced it has closed an approximately C$2.2 million ($1.67 million) non-brokered private placement offering...
You must be a Standard 1 Year member to access this content.
Fasken advised the Delta Resources, while Cassels acted for the underwriters in the transaction. Delta Resources Limited closed a “bought deal” private placement of (i) 7,143,000...
You must be a Standard 1 Year member to access this content.
